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Renovascular Hypertension(RVH) 
Renovascular hypertension is high blood 
pressure (greater than 140/80 mmHg) caused by 
renal artery disease.  
Proper kidney function is disrupted, however, 
when the arteries that provide blood to the 
kidneys become narrowed, a condition called 
renal artery stenosis.  
When stenosis results in reduced blood-flow, the 
kidney compensates by producing hormones that 
increase blood pressure.  
This response is a healthy one under normal 
circumstances. But when the reduction in blood-
flow is due to stenosis, blood pressure is 
increased unnecessarily. 
ICD 10 code for (RVH) 
ESC Grading of Arterial Hypertension 
                   Atherosclerosis 
Artherosclerosis, or hardening of the arteries, is a 
condition in which plaque builds up inside the arteries. 
Plaque is made of cholesterol, fatty substances, cellular 
waste products, calcium and fibrin (a clotting material in 
the blood).   
Plaque may partially or totally block the blood's flow 
through an artery in the heart, brain, pelvis, legs, arms or 
kidneys. Some of the diseases that may develop as a result 
of atherosclerosis include coronary heart disease, angina 
(chest pain), carotid artery disease, peripheral artery 
disease (PAD) and chronic kidney disease. 
Histological classification of 
artherosclerosis 

RVH 
 High blood pressure caused by renal artery 
disease may be difficult to control with 
medication.  
The good news is that renovascular 
hypertension is one of the few identifiable and 
treatable causes of high blood pressure — a 
condition that, if left untreated, can lead to 
heart attack, stroke or kidney failure. 

Epidemiology of Hypertension 
Hypertension is a common condition affecting 
approximately 20% of adults.  
 Secondary hypertension (i.e., hypertension with a 
demonstrable cause) accounts for only 5% to 10% of all 
cases of hypertension, with the remaining cases 
considered essential hypertension. 
  Renovascular hypertension is the most common type of 
secondary hypertension and is estimated to have a 
prevalence between 0.5% and 5% of the general 
hypertensive population, and it has an even higher 
prevalence among patients with severe hypertension 
and end-stage renal disease, approaching 25% in elderly 
dialysis patients. 
Aetiology of RVH 
There are varied causes of reduced renal 
perfusion with resultant renovascular stenosis 
secondary to either atherosclerotic disease (90%) 
or fibromuscular dysplasia (10%). Other less 
common etiologies include; 
  vasculitis,  
 embolic disease,  
 dissection,  
 post traumatic occlusion,  
 and extrinsic compression of a renal artery 
Diagnostic criteria for RVH 
  Ultimately, the defining criterion for renovascular 
hypertension is a fall in blood pressure after 
intervention (angioplasty, intravascular stent 
placement, or surgery). 
 
  Because of the low prevalence of renovascular 
hypertension among hypertensive patients in 
general, screening examinations on an unselected 
population without clinical features suggestive of 
renovascular hypertension are prone to false-
positive results. To improve the predictive value of 
diagnostic imaging examinations, imaging ideally is 
performed for those persons having clinical features 
associated with an increased hypertension 
Diagnostic Criteria cont’d 
likelihood of renovascular hypertension, such as; 
  An abdominal bruit  
  Malignant or accelerated hypertension,  
  Significant (diastolic pressure >110 mm Hg) 
hypertension in a young adult (<35 years of age),  
  Sudden development or worsening of hypertension,  
  Deterioration of renal function in response to 
angiotensin converting enzyme (ACE) inhibitors, 
and  
  generalized arteriosclerotic occlusive disease with 
hypertension. 
Signs and symptoms of RVH 
• Symptoms and Signs 
 
Renovascular hypertension is usually 
asymptomatic. A systolic-diastolic bruit in the 
epigastrium, usually transmitted to one or both 
upper quadrants and sometimes to the back, is 
almost pathognomonic, but it is present in only 
about 50% of patients with fibromuscular 
dysplasia and is rare in patients with renal 
atherosclerosis. 
Signs and Symptoms of RVH 
Renovascular hypertension should be suspected if; 
• Diastolic hypertension develops abruptly in a patient <30 
or>50 
• New or previously stable hypertension rapidly worsens within 
6 months 
• Hypertension is initially very severe associated with 
worsening renal function or highly refractory to drug treatment 
• Abrupt onset of severe(stage II) 
hypertension(>160/100mmHg in patients older than 55 years 
• Severe or resistent hypertension despite appropriately dosed 
multidrug(>3 agents) antihypertensive therapy 
• Negative family history of Hypertension 
• Smoking tobacco products 
• Recurrent pulmonary edema in the setting of moderate to 
severe hypertension 
 
 Abrupt increase in blood pressure over previously stable 
baseline in patients with previously well-controlled essential 
hypertension as well as patients with known renal artery 
stenosis (RAS) 
 Acute sustained rise in serum creatinine levels with 
angiotensin-converting enzyme (ACE) inhibitor therapy 
 Unprovoked hypokalemia (serum potassium level < 3.6 mEq/L, 
often associated with metabolic alkalosis) 
 Symptoms of atherosclerotic disease elsewhere in the presence 
of moderate-to-severe hypertension, particularly in patients 
older than 50 years 
 Moderate-to-severe hypertension in a patient with an 
unexplained atrophic kidney, significantly asymmetric kidneys 
(>1.5 cm difference), or diffuse atherosclerosis 
Signs and symptoms of RVH 
 Laboratory Diagnostics of RVH 
 
 Complete blood count (CBC) 
 Urinalysis 
 Urine culture (all girls, selected boys) 
 Serum electrolyte levels (sodium, potassium, chloride, 
and total carbon dioxide) 
 Blood urea nitrogen (BUN) levels 
 Serum creatinine levels 
 Lipid profile 
 Blood glucose and Glucose tolerance test 
 
Instrumental Diagnotics of RVH 
• Initial identification with ultrasonography, magnetic 
resonance angiography, or radionuclide imaging 
• Confirmation with renal angiography (also may be 
therapeutic) 
• If renovascular hypertension is suspected, 
ultrasonography, magnetic resonance angiography 
(MRA), or radionuclide imaging may be done to 
identify patients who should have renal angiography, 
the definitive test. 
• Renal doppler ultrasound is most affordable method 
for diagnosis  
CT Scan Kidneys and Renal arteries 
Doppler Ultrasound of Renal Artery 
Stenosis 
Indications for diagnosis of (RVH) 
Pharmacological treatment of RVH 
•The obvious goal of treatment of renovascular 
hypertension is control of blood pressure, and 
prevention of the long-term sequelae of poorly 
controlled hypertension, including renal and 
cardiac failure. 
• With the advent of medicines such as angiotensin-
converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) control of 
blood pressure can almost uniformly be maintained. 
However, because these medications can alter renal 
blood flow and function, close monitoring of 
overall renal function is paramount. If control of 
blood pressure sacrifices renal function, direct renal 
artery intervention may be warranted 
Surgical Treatment of RVH 
This may involve percutaneous intervention 
with a renal stent or an open surgery with a 
renal bypass or renal artery reconstruction. 
Lifestyle changes may be recommended, 
including weight loss, exercise, and dietary 
adjustments. Stop smoking. Stop drinking 
alcohol. These habits add to the effects of 
hypertension in causing complications. 
Stenting Procedure 
Case study 
Patient profile : 
• Name; M.V 
• Gender; Male 
• Age; 64 
• Address; Kharkiv region, Kharkiv, Ukraine 
Complaints 
Poorly controlled blood pressure since 
November 2013 
Hot feeling in the head, noise in the ears 
Headache 
Blurred vision and color blindness during 
episodes of dizziness 
Anamnesis Morbi 
• From young age registered blood pressure (BP) 
up to 130/100mmHg.  
• BP persistent increase to 160/100mmHg. 
• From November 2013 BP persistent increases up 
to 240/140mmHg - 270/150mmHg. Was treated 
in Outpatient department with multidrug therapy: 
• B-blockers 
• Calcium channel blockers 
• ACE inhibitors 
without improvement  and was  referred to Central 
Hospital No 5.  
 
Anamnesis Vitae 
• Patient denies any history of chronic 
diseases; diabetes, rheumatic disease . 
• No history of chronic infections; hepatitis 
B, Tuberculosis, Syphilis. 
• There is no family history of premature 
cardiovascular diseases 
• He is a non- smoker and says he does not 
drink. 
• Patient denies eating salty and fatty foods 
• Mr is not on any drugs other than his 
antihypertensive medications 
• He denies any history of drug allergies 
Physical Examination 
Somatic status: 
 Patient is active and alert, musculoskeletal system is 
well developed. Xanthelazma palbebrarum on left 
upper eyelid. Auscultation of breath sounds is 
without abnormalities. Heart activity is rhythmic, 
heart sounds are muted. Pulse 78bpm, Blood 
pressure 200/90mmHg. Abdomen enlarged because 
of increased fat. Liver is located at the subcostal 
margin and is not tender.  
Systolic bruit above projection of right renal artery. 
Physiological functions are normal. Negative 
Pasternatsky sign on both sides, no edema of the 
legs. 
Risk factors for CVD: arterial hypertension, signs of 
hyperlipidemia, excess body weight. 
Plan of Management 
Basic investigations 
•Full Blood Count 
• Blood Urea, Electrolytes and Glucose 
•12 leads Electrocardiogram 
•Lipid Profile 
•Heart ultrasound  
Additional investigations 
• Test for Syphilis and Helminths 
• Stress test 
•Renal artery angiography 
•Ophtamologist Consultation 
•Endovascular Surgeon Consultation 
Complete Blood Count (CBC) 
Hemglobin 153 120-140(g/l) 
Erythrocytes 5.11 3.9-4.7(T/l) 
Color index: 0.89  
 
0.89 0.85-1.15 
Leucocytes:  (4.0-9.0 g/L) 
 
7.3 4.0-9.0 (g/l)  
Neutrophils: 45.1  
 
45.1 47-72% 
Eosinophils:  9  (0.5-5.0%) 
Basophils 
 
0.7  (0-1.0%) 
 
CBC cont’d 
Lymphocytes 42.3  (19.0-37.0%) 
Monocytes 7.0 (3-11%) 
Thrombocytes 196 (180-320 g/L) 
Hematocrit 
 
64.9  (36-42%) 
 
Urinalysis  
Specific gravity:  
pH: 6.5 (5-7) 
Protein 
Glucose 
 
 
1.018 
6.5 
- 
- 
 
(0.001-1.040) 
(5-7) 
- 
- 
Lab test  
 
Blood biochemistry 27-08-14 
Glucose 
Creatinine 
Blood investigation by 
ELFA 2 
HbsAg 
HBCT 
HCV 
Glycylated Hb 
 
 
8.93 
145 
 
 
Negative  
Negative  
Negative  
5.41 
 
4.2-6.1(mmol/l) 
53-97(mmol/l) 
 
 
 
 
 
4-6% 
Electrocardiogram 
Sinus rhythm, heart rate 74, left axis deviation, 
hypertrophy of the myocardium of the left ventricle 
1- Acoustic Window Normal 
2- Aorta D.; 34.2 mm (normal (20-37 mm). Aortic walls are of increased echo density 
with a folded valve. 
    Ascending Aorta D; 39.3 mm – widened 
3- Aortic Valve Ampl. of opening of leaflets; 15.8 (17-26mm) regurgitation findings; 
Physiologic. Vmax; 205.5 cm/sec. P.G. max 16.9 mmHg. P.G. avr.; 4.5 
mmHg. 
4- Left Atrium Anteroposterior size; 32.2 (21-37).  
Leaflets of the Mitral Valve are of increased echo density and thickened. 
Movements are of different directions. 
5- Mitral Valve Ampl. of opening of leaflets; 29.2 (26-35) VmaxE; 76.6 cm/sec VmaxA; 
91.1 cm/sec. P.G. maxE; 2.3 mmHg. P.G.maxA; 3.3 mmHg. 
6- Speed of the Diastolic Opening 69.0 (50-180 cm/sec).  
regurgitation findings; Physiological. 
Mitral-Septal (E-septum); 5.9 (0-10 mm). 
7- Left Ventricle End-Diastolic pressure; 36.3 (35-55 mm). 
End-Systolic pressure; 32.9 (23-38 mm).  
Posterior wall of Left Vent.; 16.2 (6-11mm) 
EF; 56% (55-78%). 
FS; 29% (28-44%). 
Ampl. of post. Wall. Of LV; 8.6 (7-13 mm). 
LV cavity – not widened. 
Contraction – normokinetic. 
Presence of aneurism – N/A. 
 
Cardiac Ultrasonography 
8- Interventricular Septum Thickness; 16.0 (6-11 mm). 
Ampl. of movement; 4.6 (4-10mm). 
9- Right Ventricle D.; 35.4 mm (9-26 mm). 
Thickness of the wall 6.0 (3-6 mm). 
10- Interauricular Septum normal 
11- Tricuspid Valve movement of leaflets are of different directions. 
regurgitation; 1 leaflet. 
12- Pulmonary Valve movment of leaflets are of different directions. regurgitation; 1 leaflet. 
Avr. P. PA; 21.7 mmHg. 
Wave ampl. 4.1 (4-10 mm). 
Vmax; 80.3 cm/sec. 
 P.G. max; 2.6 mmHg. 
P.G. med; 0.6 mmHg. 
 
Cardiac Ultrasonography 
cont’d 
Cardiac Ultrasonography cont’d 
 
CONCLUSION  
 Sclerotic changes in the walls of the aorta, 
Leaves of   aortic and mitral valve. Dilatation 
of the ascending aorta. 
 Mild atherosclerotic aortic stenosis. 
• Hypertrophy of left ventricle (concentric type). 
• Increased diastolic stiffness of the myocardium 
of the left ventricle. 
• Tricuspid regurgitation 1st stage 
• Pulmonary valve regurgitation 1st stage 
• Signs of pulmonary hypertension 1st stage. 
Treadmill Stress test 
• Maximum oxygen consumption 7.0 mets.  
• No signs of coronary insufficiency according to 
effort. Test is negative. 
• Although there was no evidence for the need to 
provide the treadmill stress test, but it was 
carried out anyway. 
 
Preliminary Diagnosis 
• Atherosclerotic disease with peripheral 
artery involvement 
• Right renal artery stenosis 
• Renovascular hypertension stage II, Level 
3 
• Heart failure stage IIA, FC II 
 

Lifestyle Change 
Received in hospital Doctor’s recommendation Our recommendation 
1. Bisoprolol (5mg) • Lorista 100mg in 
morning 
Atorvastatin 20 mg od 
after supper 
(titration up to target 
levels of LDL-C 1,7 
mmol/L) 
2. Losartan (25mg) • Korenfar 40mg evening Losartan 25 mg od at 
bedtime 
 
3. Nifedipine (10mg)  Bisoprolol 5 mg in the 
morning (target 
HR=60/min) 
 
4. Betaxolol (lorken)                   
(20mg) 
 
• Lorken 10mg in 
morning 
Aspirin 100 mg od 
 
5. Pantprozole (nolpaza)                
(40mg) 
• Nolpaza 40mg at night 
2 weeks, small doses 
as needed for 
epigastric pain 
 
Clopidogrel 75 mg od 
 
6. Acetylcystein (acc long) 
(600mg) 
• Stugeron 1 tablet x3 
daily for 1 month 
7. Aluminium       (Almagel)               
(200mg) 
 
• Magurol 2mg at night 
 
8. hydroxide • Plaveks 75mg at 
evening after food 
 
9. Clopidogrel (plaveks).               
(75 mg) 
 
10. Euphylin IV, Latren iv 
Medication’ treatment 
Renal Angiography and Stenting 
• Angiography of renal arteries  
Renal arteries exit at the level of L1.  
Left renal artery without abnormalities.  
80% stenosis of the right renal artery. Stenting 
of right renal artery was performed (tsunami 
peripheral) 5.0x18mm. 
Renal Artery Stenting 
Renal Artery Stenting cont’d 
Renal Artery Stenting cont’d 
Renal Artery Stenting cont’d 
Treatment  
• Condition 
• Improved, pressure was lowered to 120-
140/80mmHg with the help of the 
medication. Periodic bouts of dizziness.Unfit 
for work because of the renal artery stenting. 
Discharged but indicated for followup. 
Changes in BP of Mr M.V 
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Final Diagnosis 
Atherosclerotic disease. Atherosclerosis of aorta.  
Mild aortic valve stenosis of atherosclerotic 
genesis. Occlusive (80%) atherosclerosis of the 
right renal artery (angiography of renal arteries 
28/08/2014). Condition after stenting of the right 
renal artery ( 28/08/2014). 
Secondary renovascular hypertension stage II, 
Level 3, Total Cardiovascular Risk Very High. 
Hypertensive heart (LVH).  
Heart failure stage IIA, with preserved systolic 
function of the left ventricle, II Functional Class 
 
Peculiarities of the Given 
Clinical Case. 
In this case we can see so called vicious circle: 
Arterial hypertension as well-known potent risk factor promoted 
accelerated progression of atherosclerosis.  
Atherosclerosis involved renal artery with its occlusion and development 
of secondary renovascular arterial hypertension yet. 
Secondary hypertension as more resistant to therapy further increased the 
total cardiovascular risk and accelerated progression of atherosclerosis 
Possibly timely and aggressive correction of cardiovascular 
risk (first of all optimal control of BP, hypolipidemic therapy 
with statins) would be able to slow down the progression of 
atherosclerosis and even to prevent the development of 
secondary hypertension 
Prognosis 
Untreated atherosclerotic RVH will likely progress to a greater 
degree of stenosis within 2 years. Typically, it progresses at a 
rate of 7% per year. It is also likely to become bilateral, impair 
renal function, and develop into ischemic nephropathy, 
pulmonary edema, or congestive heart failure. Pulmonary 
edema and congestive heart failure are more likely with bilateral 
disease. 
 
Studies indicate that atherosclerotic renovascular hypertension 
treated with revascularization surgery or angioplasty has a cure 
rate of 15% to 44%, improvement rate of 50% to 75%, failure 
rate of 21%, and with follow-up of 8 to 9 years, cure or 
improvement rate of 79% (Novick 253). Likelihood of cure or 
improvement is greater with unilateral disease. 
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